596 related articles for article (PubMed ID: 33047272)
1. Profilin 2 (PFN2) promotes the proliferation, migration, invasion and epithelial-to-mesenchymal transition of triple negative breast cancer cells.
Ling Y; Cao Q; Liu Y; Zhao J; Zhao Y; Li K; Chen Z; Du X; Huo X; Kang H; Chen Z
Breast Cancer; 2021 Mar; 28(2):368-378. PubMed ID: 33047272
[TBL] [Abstract][Full Text] [Related]
2. Loss of profilin 2 contributes to enhanced epithelial-mesenchymal transition and metastasis of colorectal cancer.
Zhang H; Yang W; Yan J; Zhou K; Wan B; Shi P; Chen Y; He S; Li D
Int J Oncol; 2018 Sep; 53(3):1118-1128. PubMed ID: 30015842
[TBL] [Abstract][Full Text] [Related]
3. MiR-92b inhibited cells EMT by targeting Gabra3 and predicted prognosis of triple negative breast cancer patients.
Li YY; Zheng XH; Deng AP; Wang Y; Liu J; Zhou Q; Cheng GY; Jiang Q
Eur Rev Med Pharmacol Sci; 2019 Dec; 23(23):10433-10442. PubMed ID: 31841197
[TBL] [Abstract][Full Text] [Related]
4. Loss of RAB1B promotes triple-negative breast cancer metastasis by activating TGF-β/SMAD signaling.
Jiang HL; Sun HF; Gao SP; Li LD; Hu X; Wu J; Jin W
Oncotarget; 2015 Jun; 6(18):16352-65. PubMed ID: 25970785
[TBL] [Abstract][Full Text] [Related]
5. PRAME promotes epithelial-to-mesenchymal transition in triple negative breast cancer.
Al-Khadairi G; Naik A; Thomas R; Al-Sulaiti B; Rizly S; Decock J
J Transl Med; 2019 Jan; 17(1):9. PubMed ID: 30602372
[TBL] [Abstract][Full Text] [Related]
6. Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial-mesenchymal transition (EMT) to mesenchymal-epithelial transition (MET) states.
Yoshida T; Ozawa Y; Kimura T; Sato Y; Kuznetsov G; Xu S; Uesugi M; Agoulnik S; Taylor N; Funahashi Y; Matsui J
Br J Cancer; 2014 Mar; 110(6):1497-505. PubMed ID: 24569463
[TBL] [Abstract][Full Text] [Related]
7. MiR-212-5p Suppresses the Epithelial-Mesenchymal Transition in Triple-Negative Breast Cancer by Targeting Prrx2.
Lv ZD; Yang DX; Liu XP; Jin LY; Wang XG; Yang ZC; Liu D; Zhao JJ; Kong B; Li FN; Wang HB
Cell Physiol Biochem; 2017; 44(5):1785-1795. PubMed ID: 29216628
[TBL] [Abstract][Full Text] [Related]
8. Silencing of Prrx1b suppresses cellular proliferation, migration, invasion and epithelial-mesenchymal transition in triple-negative breast cancer.
Lv ZD; Yang ZC; Liu XP; Jin LY; Dong Q; Qu HL; Li FN; Kong B; Sun J; Zhao JJ; Wang HB
J Cell Mol Med; 2016 Sep; 20(9):1640-50. PubMed ID: 27027510
[TBL] [Abstract][Full Text] [Related]
9. PFN2, a novel marker of unfavorable prognosis, is a potential therapeutic target involved in esophageal squamous cell carcinoma.
Cui XB; Zhang SM; Xu YX; Dang HW; Liu CX; Wang LH; Yang L; Hu JM; Liang WH; Jiang JF; Li N; Li Y; Chen YZ; Li F
J Transl Med; 2016 May; 14(1):137. PubMed ID: 27188458
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of iNOS as a novel effective targeted therapy against triple-negative breast cancer.
Granados-Principal S; Liu Y; Guevara ML; Blanco E; Choi DS; Qian W; Patel T; Rodriguez AA; Cusimano J; Weiss HL; Zhao H; Landis MD; Dave B; Gross SS; Chang JC
Breast Cancer Res; 2015 Feb; 17(1):25. PubMed ID: 25849745
[TBL] [Abstract][Full Text] [Related]
11. MicroRNA-543 inhibits the proliferation, migration, invasion, and epithelial-mesenchymal transition of triple-negative breast cancer cells via down-regulation of ACTL6A gene.
Wang YL; Liang RH; Wang CY; Zhang RP; Wu SY; Han X; Zhang GL
Clin Transl Oncol; 2022 Jan; 24(1):84-92. PubMed ID: 34181232
[TBL] [Abstract][Full Text] [Related]
12. Suppression of KIF3A inhibits triple negative breast cancer growth and metastasis by repressing Rb-E2F signaling and epithelial-mesenchymal transition.
Wang W; Zhang R; Wang X; Wang N; Zhao J; Wei Z; Xiang F; Wang C
Cancer Sci; 2020 Apr; 111(4):1422-1434. PubMed ID: 32011034
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of SERPINA3 promotes tumor invasion and migration, epithelial-mesenchymal-transition in triple-negative breast cancer cells.
Zhang Y; Tian J; Qu C; Peng Y; Lei J; Li K; Zong B; Sun L; Liu S
Breast Cancer; 2021 Jul; 28(4):859-873. PubMed ID: 33569740
[TBL] [Abstract][Full Text] [Related]
14. Knockdown of endothelin receptor B inhibits the progression of triple-negative breast cancer.
Gu X; Han S; Cui M; Xue J; Ai L; Sun L; Zhu X; Wang Y; Liu C
Ann N Y Acad Sci; 2019 Jul; 1448(1):5-18. PubMed ID: 30900271
[TBL] [Abstract][Full Text] [Related]
15. PKMYT1 Promotes Epithelial-Mesenchymal Transition Process in Triple-Negative Breast Cancer by Activating Notch Signaling.
Li B; Huang L; Ruan J
Rev Invest Clin; 2024; 76(1):45-59. PubMed ID: 38442372
[TBL] [Abstract][Full Text] [Related]
16. Upregulation of MGP by HOXC8 promotes the proliferation, migration, and EMT processes of triple-negative breast cancer.
Gong C; Zou J; Zhang M; Zhang J; Xu S; Zhu S; Yang M; Li D; Wang Y; Shi J; Li Y
Mol Carcinog; 2019 Oct; 58(10):1863-1875. PubMed ID: 31264274
[TBL] [Abstract][Full Text] [Related]
17. miR-122-5p promotes aggression and epithelial-mesenchymal transition in triple-negative breast cancer by suppressing charged multivesicular body protein 3 through mitogen-activated protein kinase signaling.
Wang Z; Wang X
J Cell Physiol; 2020 Mar; 235(3):2825-2835. PubMed ID: 31541468
[TBL] [Abstract][Full Text] [Related]
18. Upregulation of FGF9 and NOVA1 in cancer-associated fibroblasts promotes cell proliferation, invasion and migration of triple negative breast cancer.
Zhang B; Liu Y; Yu J; Lin X
Drug Dev Res; 2024 May; 85(3):e22185. PubMed ID: 38657094
[TBL] [Abstract][Full Text] [Related]
19. Overexpression of NuSAP1 is predictive of an unfavourable prognosis and promotes proliferation and invasion of triple-negative breast cancer cells via the Wnt/β-catenin/EMT signalling axis.
Sun L; Shi C; Liu S; Zhang E; Yan L; Ji C; Zhao Y
Gene; 2020 Jul; 747():144657. PubMed ID: 32298762
[TBL] [Abstract][Full Text] [Related]
20. Heterogeneous nuclear ribonucleoprotein A2/B1 is a negative regulator of human breast cancer metastasis by maintaining the balance of multiple genes and pathways.
Liu Y; Li H; Liu F; Gao LB; Han R; Chen C; Ding X; Li S; Lu K; Yang L; Tian HM; Chen BB; Li X; Xu DH; Deng XL; Shi SL
EBioMedicine; 2020 Jan; 51():102583. PubMed ID: 31901866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
